Both Spravato and oral ketamine come from the same family of medication, and both are used to treat depression that hasn’t responded to standard antidepressants. But they work differently enough that the choice between them can give you a hard time. Understanding where they differ can make the decision a lot less overwhelming.
What Is Spravato?
Spravato is the brand name for esketamine, the S-enantiomer of ketamine, isolated and formulated specifically for nasal delivery. It’s FDA-approved and administered exclusively in certified clinical settings under direct medical supervision, following a standardized fixed-dose protocol of 56mg or 84mg per session under REMS program guidelines.
Spravato is FDA-approved for two distinct indications:
- Adults with treatment-resistant depression, either as a standalone treatment or alongside an oral antidepressant.
- Adults with major depressive disorder experiencing acute suicidal ideation, in conjunction with an oral antidepressant.
What Is Oral Ketamine?
Oral ketamine is racemic ketamine, meaning it contains both the R- and S-enantiomers, taken as a sublingual lozenge or tablet rather than administered through an IV infusion or nasal spray. It’s prescribed off-label for depression, since ketamine itself doesn’t currently hold FDA approval for any depression-related indication in any form.
That doesn’t mean it isn’t well-studied or effective. Off-label prescribing is common and well-established in mental health care, and oral ketamine has become a widely used option, particularly for patients who want a more flexible, lower-intensity introduction to ketamine-based treatment, or who are using it in conjunction with structured psychotherapy.
Core Differences Between Spravato vs. Oral Ketamine
On paper, Spravato and oral ketamine share the same core mechanism. In practice, they do have important distinctions. The ones that tend to matter the most to patients are:
- Regulatory status and insurance
- Composition
- Bioavailability and intensity
- Structure and supervision
Regulatory Status and Insurance
This is the most practically significant difference for most patients. Spravato’s FDA approval means it fits within standard insurance frameworks for covered psychiatric treatment. It is covered by most major insurers, including Blue Cross Blue Shield, UnitedHealthcare, Aetna, and Cigna, for patients who meet the clinical criteria.
Oral ketamine, prescribed off-label, typically doesn’t fit within standard insurance frameworks, and the cost of a full ketamine treatment course adds up when it’s entirely out of pocket.
Composition
Spravato contains only esketamine (the S-enantiomer). Oral ketamine is racemic, containing both R- and S-enantiomers. Some research suggests the R-enantiomer may contribute to antidepressant effects and could be associated with longer-lasting benefits, though this remains an active area of study rather than settled science.
Neither has been proven definitively superior in large-scale, head-to-head clinical trials. In practice, this means the choice between them often comes down less to “which is more powerful” and more to what fits your diagnosis, treatment history, and the kind of structure you’re looking for.
Bioavailability and Intensity
Spravato’s intranasal delivery produces more predictable absorption than oral administration and typically results in a more pronounced altered state.
With oral ketamine, much of the dose is broken down in the liver before it ever reaches the bloodstream. Sublingual administration (dissolving under the tongue) bypasses some of that, allowing the medication to absorb directly through the oral mucosa, but bioavailability still sits at roughly 20–30%. What that typically means in practice is a more gradual, gentler experience, which some patients actually prefer, particularly those sensitive to dissociative effects.
Structure and Supervision
Both treatments should be administered under clinical supervision. Spravato requires it through the REMS guidelines. Oral ketamine protocols vary by provider. Some clinics administer it on-site, while others prescribe it for supervised at-home use, which introduces more variability to the experience.
Which Therapy May Be Right for You
Neither option is universally “better.” The right choice depends on your diagnosis, treatment history, and what kind of structure and support you’re looking for.
Spravato may be a better fit if:
- You’ve been formally diagnosed with treatment-resistant depression.
- You’ve been formally diagnosed with major depressive disorder with acute suicidal ideation.
- You want a treatment with FDA approval and standardized dosing.
- Insurance coverage is an important factor in your decision.
Oral ketamine may be a better fit if:
- You’re looking for a more flexible, gradual approach
- You’re using it as part of a broader psychotherapy-integrated treatment plan
- Your symptoms don’t meet the formal clinical threshold required for a Spravato prescription
- You prefer a treatment approach that some patients experience as less intense than intranasal esketamine
Neither path requires you to have it all figured out before you start the conversation. Both are real, evidence-supported therapies. Which one fits your situation is something worth working through with a provider who can look at your full history.
Let’s Talk Through Your Options Together
Choosing between Spravato and oral ketamine isn’t something you should have to sort out alone, especially while you’re already carrying the weight of depression that hasn’t responded to other treatments. Our free consultation is the place to bring your questions, your history, and your uncertainty without pressure or commitment. Just an honest conversation about what might actually help.
